Microscopic polyangiitis associated with antineutrophil cytoplasmic antibodies: Clinical features


Cite item

Full Text

Abstract

Aim. To study the clinical features of early- and extended-stage microscopic polyangiitis (MPA) and its outcomes on the basis of a long-term follow-up in a rheumatologist’s practice. Subjects and methods. The clinical features of early- and extended-stage MPA were studied in detail and the premorbid background and possible precipitating factors were analyzed in 70 patients with MPA and the proven hyperproduction of antineutrophil cytoplasmic antibodies (anti-proteinase-3 (anti-PR3) antibodies in 55% and anti-myeloperoxidase (anti-MPO) antibodies in 45%) who had been followed up for more than a year. Results. There is evidence for the nosological unity of the two immunological types of MPA associated with anti-PR-3 or anti-MPO antibodies. MPA has been demonstrated to be an aggressive, polysyndromic disease prone to recurrences (52%), the typical manifestation of which is glomerulonephritis (94%) that is rapidly progressive in every four cases and accompanied by hemorrhagic alveolitis (69%) and involvement of other organs. ENT organs and lungs have been noted to be commonly involved in early-stage MPA, which was observed in 61% of the patients in the premorbid period, and to become the first manifestation of MPA (63%) concurrent with body temperature rises (64%), arthralgia or arthritis (41%). Respiratory tract involvement in MPA may be asymptomatic. Anti-PR-3-associated MPA may manifest itself more aggressively and in the first 2 years it is characterized by a poorer prognosis than of anti-MPO-associated MPA (survival rates, 82 and 94%, respectively; p=0.04). With time, the differences were levelled off; recurrences in the patients with anti-PR-3 and anti-MPO develop equally frequently and proceed showing the similar clinical picture; the survival curves converge by age 3. Anti-MPO-associated MPA is characterized by the highest rate of lung involvement in the clinical phase of the disease (61%) and by a propensity to develop hemorrhagic alveolitis, diffuse interstitial (22%) or circumscribed pulmonary fibrosis in the outcome. Conclusion. The findings emphasize how important to diagnose MPA early and to prescribe long-term active treatment using the entire current arsenal of medications as soon as possible until severe injury to organs and systems develops. To specify regularities in the development of MPA may be of value for the better diagnosis of the disease and the further elaboration of optimal treatment policy.

About the authors

T V Beketova

References

  1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
  2. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW, Masi AT, McShane DJ, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ. The American College of Rheu­matology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33:1101-1107.
  3. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lightfoot RW, McShane DJ, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094-1100.
  4. Fries JF, Hunder GG, Bloch DA, Calabrese LH, Fauci AS, Fries JF, Leavitt RY, Lie JT, Lightfoot RW, Masi AT, McShane DJ, Michel BA, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 1990;33(8):1135-1136.
  5. Huang Ch-K, Fang H-Ch, Chou K-J, Wang J-S, Lee P-T, Chang T-Y, Hsu Ch-Y, Huang W-Ch, Chung H-M and Chen Ch-L. Clinical Features of Microscopic Polyangiitis: A Cohort Study in a Southern Taiwan Medical Center Acta Nephrologica. 2012;26(4):198-205.
  6. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM. 2005;98:97-111.
  7. Guillevin L, Lhote F, Amouroux J, Gherardi R, Callard P, Cassaus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg—Strauss syndrome: indications for the classification of vasculitides of the Polyarteritis Nodosa Group. Br J Rheumatol. 1996;35:958-964.
  8. Бекетова Т.В. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;6(50):19-28.
  9. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N. EULAR/PRINTO/PRES criteria for Henoch—Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis. 2010;69(5):798-806.
  10. Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C, Coste J, Guillevin L. Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology. 2010;49:2181-2190.
  11. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. AnnRheum Dis. 2007;66:222-227.
  12. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686.
  13. Luqmani R, Bacon P, Moots R, Janssen B, Pall A, Emery P, Savage C, Adu D. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671-678.
  14. Wohlwill F. Ueber die nur mikroskopisch erkennbare Form der Periarteriitis nodosa. Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin, Berlin 1923 246:377-411.
  15. Savage C, Winearls C, Evans D, Rees A, Lockwood C. Microscopic polyarteritis: presentation, pathology and prognosis. QJ Med. 1985;56:467-483.
  16. Van der Woude F, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es L, van Es LA, van der Giessen M, van der Hem GK, The TH. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet. 1985;1:425-429.
  17. Gross W, Schmitt W, Csernok E. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol. 1993;91:1-12.
  18. Kallenberg C, Brouwer E, Weening J, Cohen Tervaert J. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiologic potential. Kidney Int. 1994;46:1-15.
  19. Jennette J, Falk R. Anti-neutrophil cytoplasmic autoantibodies: discovery, specificity, disease associations and pathogenic potential. Adv Pathol Lab Med. 1995;8:363-378.
  20. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41:1521-1537.
  21. Jennette J, Falk R, Andrassy K, Bacon P, Churg J, Gross W, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CGM, Mccluskey RT, Sinico RA, Rees AJ, Es LAV, Waldherr R, Wiik A. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-192.
  22. Бекетова Т.В. Клинико-иммунологические особенности гранулематоза Вегенера и микроскопического полиангиита: Дис. ... канд. мед. наук; 1994.
  23. Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener‘s granulomatosis, microscopic polyangiitis, Churg—Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009;48(12):1560-1565.
  24. Adu D, Howie AJ, Scott DGI, Bacon PA, McGonigle RJS, Michael J. Polyarteritis and the kidney. Q J Med. 1987;62:221-237.
  25. Rodgers H, Guthrie JA, Brownjohn AM and Turney JH. Microscopic polyarteritis: clinical features and treatment. Postgraduate Med J. 1989;65:515-518.
  26. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421-430.
  27. Ahn JK, Hwang JW, Lee J, Jeon CH, Cha HS, Koh EM. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int. 2011;32:2979-2986.
  28. Fuiano G, Cameron JS, Raftery M Hartley BH, Williams DG, Ogg CS. Improved prognosis of renal microscopic polyarteritis in recent years. Nephrol Dial Transplant. 1988;3:383-391.
  29. Lanham J, Elkon K, Pusey C, Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg—Strauss syndrome. Medicine. 1984;63:65-81.
  30. Бекетова ТВ Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;6:19-28.
  31. Douglas G, Bird K, Flume P, Silver R, Bolster M. Wegener’s granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003;30:2064-2069.
  32. Rodgers H, Guthrie JA, Brownjohn AM, Turney JH. Microscopic polyarteritis: clinical features and treatment. Postgraduate Med J. 1989;65:515-518.
  33. Стрижаков Л.А., Моисеев С.В., Семенкова Е.Н., Коган Е.А., Паша С.П., Кузнецова Е.И., Диттерле В.Е., Мухин Н.А. Клинико-патоморфологические варианты поражения сердца убольных системными васкулитами и возможности неинвазивных методов диагностики. Фарматека. 2013;9: 65-71.
  34. Lauque D, Cadranel J, Lazor R, Pourrat J, Ronco P, Guillevin L, Cordier J. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d’Etudes et de Recherche sur les Maladies «Orphelines» Pulmonaires (GERM«O»P). Medicine (Baltimore). 2000;79(4):222-233.
  35. Nada AK, Torres VE, Ryu JH, Lie JT, Holley K. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc. 1990;65:847-856.
  36. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004;9(2):190-196.
  37. Foulon G, Delaval P, Valeyre D, Wallaert B, Debray MP, Brauner M, Nicaise P, Cadranel J, Cottin V, Tazi A, Aubier M, Crestani B. ANCA-associated lung fibrosis: Analysis of 17 patients Foulon, Guillaume et al. Respiratory Med. 2008;102(10):1392-1398.
  38. Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, Hamidou MA. Pulmonary fibrosis associated with ANCA-positive vasculitides. Ann Rheum Dis. 2009;68(3):404-407.
  39. Nakabayashi K, Fujioka Y, Nagasawa T, Kimura T, Kojima K, Arimura Y, Yamada A. Dual myeloperoxidase-antineutrophil cytoplasmic antibody-and antiglomerular basement membrane antibody-positive cases associated with prior pulmonary fibrosis: a report of four cases. Clin Exp Nephrol. 2011;15(2):226-234.
  40. Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, Ito T, Nureki S, Kumamoto T. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107(4):608-615.
  41. Cambridge G, Williams M, Leaker B, Corbett M, Smith CR. Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass. Ann Rheum Dis. 1994;53:24-29.
  42. Braun MG, Csernok E, Schmitt WH, Gross WL. Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. J Rheumatol. 1996;23:826-830.
  43. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90:19-27.
  44. Chen Y, Zhang W, Chen X, Ni L, Shen P, Wang W, Chen N. Clinical analysis of ANCA-associated renal vasculitis patients with chronic dialysis. Clin Exper Rheumatol. 2014;32(Suppl 82):11-18.
  45. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant. 2004;19:1403-1411.
  46. Stangou M, Asimaki A, Bamichas G, Christidou F, Zoumbaridis N, Natse T, Galanis N, Christaki P, Patakas D, Sombolos K. Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: A single-center experience. J Nephrol. 2005;18:35-44.
  47. Wiik A. Clinical and pathophysiological significance of anti-neutrophil cytoplasmic autoantibodies in vasculitis syndromes. Mod Rheumatol. 2009;19:590-599.
  48. Jayne D, Gaskin G, Pusey C, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM. 1995;88: 27-133.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies